
浏览全部资源
扫码关注微信
陕西中医药大学基础医学院生物化学教研室,咸阳 712046
雒世婷,Email:2065148094@qq.com,研究方向:肝脏疾病的发病机制及中医药防治机理的研究。
史晓燕,Email:biosalome@163.com。
收稿:2024-04-08,
修回:2024-07-27,
录用:2024-10-10,
纸质出版:2025-07-28
移动端阅览
雒世婷,史晓燕.铁代谢异常对代谢相关脂肪性肝病的影响及治疗研究进展[J].重庆医科大学学报,2025,50(7):945-950.
Luo Shiting,Shi Xiaoyan.Research advances in the effect of iron metabolism disorders on metabolic associated fatty liver disease and related treatment methods[J].Journal of Chongqing Medical University,2025,50(7):945-950.
雒世婷,史晓燕.铁代谢异常对代谢相关脂肪性肝病的影响及治疗研究进展[J].重庆医科大学学报,2025,50(7):945-950. DOI: 10.13406/j.cnki.cyxb.003723.
Luo Shiting,Shi Xiaoyan.Research advances in the effect of iron metabolism disorders on metabolic associated fatty liver disease and related treatment methods[J].Journal of Chongqing Medical University,2025,50(7):945-950. DOI: 10.13406/j.cnki.cyxb.003723.
铁是人体含量、需要量最多的微量元素,对人体的正常代谢和生命活动至关重要。肝脏是铁的主要储存器官,铁代谢紊乱对肝脏有着多方面的危害,与多种肝脏疾病的发生发展有关。近年来,代谢相关脂肪性肝病逐渐成为了全球高发的肝脏疾病,其发生发展受铁代谢等多种因素影响,涉及不同的分子机制。本文综述了铁代谢异常对代谢相关脂肪性肝病的影响,同时总结了基于铁代谢异常对代谢相关脂肪性肝病的治疗方法,以期为代谢相关脂肪性肝病的防治提供更多思路。
Iron,which has the highest content and is the most required trace element in the human body,is vital to the normal metabolism and life activities of our body. The liver is the main storage organ of iron,and iron metabolism disorders have various harms to the liver and are associated with the development and progression of a variety of liver diseases. In recent years,metabolic associated fatty liver disease has become a liver disease with a high incidence rate globally,and its development and progression are affected by many factors such as iron metabolism and involves different molecular mechanisms. This article reviews the effect of iron metabolism disorders on metabolic associated fatty liver disease and summarizes the treatment methods for metabolic associated fatty liver disease based on iron metabolism disorders,in order to provide more ideas for the prevention and treatment of metabolic associated fatty liver disease.
Yiannikourides A , Latunde-Dada GO . A short review of iron metabolism and pathophysiology of iron disorders [J ] . Medicines , 2019 , 6 ( 3 ): 85 .
Dutt S , Hamza I , Bartnikas TB . Molecular mechanisms of iron and heme metabolism [J ] . Annu Rev Nutr , 2022 , 42 : 311 - 335 .
Kumar A , Sharma E , Marley A , et al . Iron deficiency anaemia:pathophysiology,assessment,practical management [J ] . BMJ Open Gastroenterol , 2022 , 9 ( 1 ): e000759 .
Candelaria PV , Leoh LS , Penichet ML , et al . Antibodies targeting the transferrin receptor 1 (TfR1) as direct anti-cancer agents [J ] . Front Immunol , 2021 , 12 : 607692 .
陈春梅 , 葛 品 , 郭翀 . 人体铁代谢及其调控因素 [J ] . 基础医学与临床 , 2022 , 42 ( 5 ): 818 - 823 .
Chen CM , Ge P , Guo C . Iron metabolism in human body and its regulatory factors [J ] . Basic Clin Med , 2022 , 42 ( 5 ): 818 - 823 .
王 蕾 , 王子琼 , 于 露 , 等 . 铁代谢及铁稳态失衡的研究进展 [J ] . 公共卫生与预防医学 , 2022 , 33 ( 3 ): 118 - 122 .
Wang L , Wang ZQ , Yu L , et al . Research progress of iron metabolism and iron homeostasis imbalance [J ] . J Public Health Prev Med , 2022 , 33 ( 3 ): 118 - 122 .
Nemeth E , Ganz T . Hepcidin and iron in health and disease [J ] . Annu Rev Med , 2023 , 74 : 261 - 277 .
Gammella E , Correnti M , Cairo G , et al . Iron availability in tissue microenvironment:the key role of ferroportin [J ] . Int J Mol Sci , 2021 , 22 ( 6 ): 2986 .
Zheng HR , Yang F , Deng KG , et al . Relationship between iron overload caused by abnormal hepcidin expression and liver disease:a review [J ] . Medicine , 2023 , 102 ( 11 ): e33225 .
Billesbølle CB , Azumaya CM , Kretsch RC , et al . Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms [J ] . Nature , 2020 , 586 ( 7831 ): 807 - 811 .
Garza KR , Clarke SL , Ho YH , et al . Differential translational control of 5' IRE-containing mRNA in response to dietary iron deficiency and acute iron overload [J ] . Metallomics , 2020 , 12 ( 12 ): 2186 - 2198 .
Ameka M , Hasty AH . Paying the iron price:liver iron homeostasis and metabolic disease [J ] . Compr Physiol , 2022 , 12 ( 3 ): 3641 - 3663 .
Xiao X , Alfaro-Magallanes VM , Babitt JL . Bone morphogenic proteins in iron homeostasis [J ] . Bone , 2020 , 138 : 115495 .
Yang L , Wang H , Yang X , et al . Auranofin mitigates systemic iron overload and induces ferroptosis via distinct mechanisms [J ] . Signal Transduct Target Ther , 2020 , 5 ( 1 ): 138 .
Zhang FL , Zhao P , Qian ZM , et al . Central nervous system inflammation induced by lipopolysaccharide up-regulates hepatic hepcidin expression by activating the IL-6/JAK2/STAT3 pathway in mice [J ] . Front Nutr , 2021 , 8 : 649640 .
Schwartz AJ , Das NK , Ramakrishnan SK , et al . Hepatic hepcidin/intestinal HIF-2α axis maintains iron absorption during iron deficiency and overload [J ] . J Clin Invest , 2019 , 129 ( 1 ): 336 - 348 .
张立加 , 蔡静明 , 沈 洁 , 等 . 铁超载对NAFLD大鼠DMT1和FPN1基因表达影响 [J ] . 中国公共卫生 , 2018 , 34 ( 5 ): 716 - 719 .
Zhang LJ , Cai JM , Shen J , et al . Effects of iron overload on gene expressions of DMT1 and FPN1 in rats with nonalcoholic fatty liver disease [J ] . Chin J Public Health , 2018 , 34 ( 5 ): 716 - 719 .
Zhu ZX , Zhang XX , Pan Q , et al . In-depth analysis of de novo lipogenesis in non-alcoholic fatty liver disease:mechanism and pharmacological interventions [J ] . Liver Res , 2023 , 7 ( 4 ): 285 - 295 .
Gao H , Jin ZM , Bandyopadhyay G , et al . Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis [J ] . Cell Metab , 2022 , 34 ( 8 ): 1201 - 1213 . e5.
Britton L , Bridle K , Reiling J , et al . Hepatic iron concentration correlates with insulin sensitivity in nonalcoholic fatty liver disease [J ] . Hepatol Commun , 2018 , 2 ( 6 ): 644 - 653 .
张 瑞 , 李荣荣 , 王腊梅 , 等 . 氧化应激在非酒精性脂肪肝发病机制中的作用和潜在治疗靶点 [J ] . 动物营养学报 , 2022 , 34 ( 12 ): 7602 - 7615 .
Zhang R , Li RR , Wang L/X)M , et al . Role of oxidative stress in pathogenesis of non-alcoholic fatty liver disease and potential therapeutic targets [J ] . Chin J Anim Nutr , 2022 , 34 ( 12 ): 7602 - 7615 .
赵丽梅 , 郭晓红 , 刘立新 . 非酒精性脂肪性肝病患者血清铁代谢及氧化应激相关指标变化的Meta分析 [J ] . 胃肠病学和肝病学杂志 , 2022 , 31 ( 10 ): 1113 - 1122 .
Zhao LM , Guo XH , Liu LX . Changes of serum iron metabolism and oxidative stress-related indexes in patients with non-alcoholic fatty liver disease:a Meta-analysis [J ] . Chin J Gastroenterol Hepatol , 2022 , 31 ( 10 ): 1113 - 1122 .
Zhang LJ , Dai XZ , Wang L , et al . Iron overload accelerated lipid metabolism disorder and liver injury in rats with non-alcoholic fatty liver disease [J ] . Front Nutr , 2022 , 9 : 961892 .
Ding H , Zhang Q , Yu X , et al . Lipidomics reveals perturbations in the liver lipid profile of iron-overloaded mice [J ] . Metallomics , 2021 , 13 ( 10 ): mfab057 .
Liang DG , Minikes AM , Jiang XJ . Ferroptosis at the intersection of lipid metabolism and cellular signaling [J ] . Mol Cell , 2022 , 82 ( 12 ): 2215 - 2227 .
Liu B , Yi W , Mao XX , et al . Enoyl coenzyme A hydratase 1 alleviates nonalcoholic steatohepatitis in mice by suppressing hepatic ferroptosis [J ] . Am J Physiol Endocrinol Metab , 2021 , 320 ( 5 ): E925 - E937 .
Jiang JJ , Zhang GF , Zheng JY , et al . Targeting mitochondrial ROS-mediated ferroptosis by quercetin alleviates high-fat diet-induced hepatic lipotoxicity [J ] . Front Pharmacol , 2022 , 13 : 876550 .
Dai X , Zhang R , Wang BM . Contribution of classification based on ferroptosis-related genes to the heterogeneity of MAFLD [J ] . BMC Gastroenterol , 2022 , 22 ( 1 ): 55 .
Miotto G , Rossetto M , Di Paolo ML , et al . Insight into the mechanism of ferroptosis inhibition by ferrostatin-1 [J ] . Redox Biol , 2020 , 28 : 101328 .
Li XY , Wang TX , Huang XM , et al . Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity [J ] . Liver Int , 2020 , 40 ( 6 ): 1378 - 1394 .
Zhu ZX , Zhang Y , Huang XH , et al . Thymosin beta 4 alleviates non-alcoholic fatty liver by inhibiting ferroptosis via up-regulation of GPX4 [J ] . Eur J Pharmacol , 2021 , 908 : 174351 .
Fan BY , Pang YL , Li WX , et al . Liproxstatin-1 is an effective inhibitor of oligodendrocyte ferroptosis induced by inhibition of glutathione peroxidase 4 [J ] . Neural Regen Res , 2021 , 16 ( 3 ): 561 - 566 .
Tong J , Lan XT , Zhang Z , et al . Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice:potential involvement of PANoptosis [J ] . Acta Pharmacol Sin , 2023 , 44 ( 5 ): 1014 - 1028 .
Lu YZ , Hu JJ , Chen L , et al . Ferroptosis as an emerging therapeutic target in liver diseases [J ] . Front Pharmacol , 2023 , 14 : 1196287 .
Yan HF , Liu ZY , Guan ZA , et al . Deferoxamine ameliorates adipocyte dysfunction by modulating iron metabolism in ob/ob mice [J ] . Endocr Connect , 2018 , 7 ( 4 ): 604 - 616 .
Chen HQ . Iron metabolism in non-alcoholic fatty liver disease:a promising therapeutic target [J ] . Liver Res , 2022 , 6 ( 4 ): 203 - 213 .
Jomen W , Ohtake T , Akita T , et al . Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths [J ] . Biomed Pharmacother , 2022 , 153 : 113363 .
Jones G , Goswami SK , Kang H , et al . Combating iron overload:a case for deferoxamine-based nanochelators [J ] . Nanomedicine , 2020 , 15 ( 13 ): 1341 - 1356 .
Abbina S , Abbasi U , Gill A , et al . Active transport nanochelators for the reduction of liver iron burden in iron overload [J ] . J Control Release , 2022 , 350 : 857 - 869 .
吴 珺 , 张馨元 , 任月乔 , 等 . 中医药调控铁死亡治疗非酒精性脂肪性肝病研究进展 [J/OL ] . 辽宁中医药大学学报 , 2024 ( 2024-04-24 ). https://kns.cnki.net/kcms/detail/21.1543.R.20240423.1600.009. html https://kns.cnki.net/kcms/detail/21.1543.R.20240423.1600.009.html .
Wu J , Zhang XY , Ren YQ , et al . Research Progress in Regulation Ferroptosis by Traditional Chinese Medicine in the Treatment of Non-alcoholic Fatty Liver Disease [J/OL ] . Journal of Liaoning University of Traditional Chinese Medicine , 2024 ( 2024-04-24 ). https://kns. cnki.net/kcms/detail/21.1543. R.20240423.1600.009.html https://kns.cnki.net/kcms/detail/21.1543.R.20240423.1600.009.html .
吕 琨 , 李 婵 , 谢萍 . 姜黄素对非酒精性脂肪肝细胞模型铁负荷的影响 [J ] . 中国老年学杂志 , 2024 , 44 ( 7 ): 1735 - 1738 .
Lü K , Li C , Xie P . Effect of curcumin on iron load in cell model of nonalcoholic fatty liver disease [J ] . Chin J Gerontol , 2024 , 44 ( 7 ): 1735 - 1738 .
秦 智 , 周 敏 . 丹参酮ⅡA通过Nrf2信号通路抑制肝组织铁死亡对非酒精性脂肪肝大鼠肝脏的保护作用 [J ] . 中国中药杂志 , 2024 , 49 ( 6 ): 1611 - 1620 .
Qin Z , Zhou M . Tanshinone ⅡA inhibits ferroptosis via Nrf2 signaling pathway to protect liver in rats of non-alcoholic fatty liver disease [J ] . China J Chin Mater Med , 2024 , 49 ( 6 ): 1611 - 1620 .
叶苗青 , 薛敬东 , 李粉萍 , 等 . 化脂复肝颗粒对非酒精性脂肪肝TLR4/NF-κB通路及脂肪铁死亡的调控及机制研究 [J ] . 现代中西医结合杂志 , 2021 , 30 ( 30 ): 3307 - 3312 .
Ye MQ , Xue JD , Li FP , et al . Study on regulation and mechanism of Huazhi Fugan Granules on TLR4/NF-κB pathway and fatty iron death in non-alcoholic fatty liver [J ] . Mod J Integr Tradit Chin West Med , 2021 , 30 ( 30 ): 3307 - 3312 .
肖倩倩 , 王梦雨 , 范建高 . 亚太肝病研究学会代谢相关脂肪性肝病临床诊疗指南(治疗部分)简介 [J ] . 临床肝胆病杂志 , 2021 , 37 ( 1 ): 41 - 45 .
Xiao QQ , Wang MY , Fan JG . Brief introduction of APASL clinical practice guidelines on metabolic associated fatty liver disease(Treatment Part) [J ] . J Clin Hepatol , 2021 , 37 ( 1 ): 41 - 45 .
倪文婧 , 李婕 , 范建高 . 《2023年美国肝病学会实践指导:非酒精性脂肪性肝病的临床评估和管理》意见简介 [J ] . 临床肝胆病杂志 , 2023 , 39 ( 5 ): 1049 - 1055 .
Ni WJ , Li J , Fan JG . A brief introduction of AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease in 2023 [J ] . J Clin Hepatol , 2023 , 39 ( 5 ): 1049 - 1055 .
0
浏览量
11
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621